Similarly, treatment with the JAK inhibitor ruxolitinib also significantly lowered the phosphorylation levels of JAK2 and STAT3 induced by hyperuricemia, achieving effects comparable to those of STAT3 knockout. Here, JAK2 is linked to hyperuricemia.